Claims Classify Iren’s Natural Products As Drugs; FDA Cites CGMP Violations
This article was originally published in The Tan Sheet
Executive Summary
FDA found "significant deviations" from current good manufacturing practices at Iren Corp.'s manufacturing facility after the agency determined the firm's claims for some products indicate their intended use as drugs, according to an April 3 warning letter